LeadArtis collaborate on next-generation Trimerbody® products

22-03-2012

LeadArtis S.L. announced that published proof-of-concept data with a new Trimerbody® molecule. Trimerbody® molecules based in human collagen XV exhibited excellent antigen binding capacity, and demonstrated greater thermal and serum stability and resistance to protease digestion than conventional type XVIII Trimerbody® molecules.
The work highlighted that the small size, high expression level, solubility and stability of the trimerization domain of type XV collagen make it an ideal choice for engineering homotrimeric antibodies to image and treat human disease. The data were published in the March/April 2012 issue of mAbs (volumen 4, issue 2, pages 226-232).

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...